

Press Release

Quadrigo Biosciences Receives \$2.0 Million Phase II SBIR Grant to Advance the Development of its Novel Targeted Treatment for Glioblastoma Multiforme

LOS ALTOS, CA, Oct. 10, 2017

Quadrigo Biosciences, a privately held, pharmaceutical company focused on developing novel, proprietary amino acid mimics for the treatment of cancer, today announced that the Company has been awarded a Phase II Small Business Innovation Research Grant (SBIR) of \$2 million from the National Institutes of Health (NIH) to support the development of its compounds for the treatment of glioblastoma multiforme (GBM), an extremely deadly form of brain cancer for which no long term effective treatment options are available.

“We appreciate the NIH’s continued recognition of our science and the importance of the development of our lead molecules for the treatment of GBM,” said Dr. Gordon Ringold, Chief Executive Office of Quadrigo Biosciences. “GBM is the most malignant form of brain cancer and new therapeutic approaches will be required to significantly impact the progression of this disease. Given the high unmet medical need, we are excited about the opportunity to advance our lead compound through preclinical development over the ensuing months and be in a position to initiate clinical trials by late next year.”

About Quadrigo Biosciences

Quadrigo Biosciences is a privately held pharmaceutical company developing proprietary, targeted cancer therapies. Our technology is based on the discovery that many aggressive forms of cancer cells over-express certain unique nutrient transporters on their cell surfaces for the uptake of nutrients, such as amino acids, to support rapid tumor growth and proliferation. Exploiting this biology, Quadrigo is developing novel small molecules to be preferentially taken up by tumors cells that over-express these transporters. Quadrigo is focusing initially on the treatment of primary brain cancer and triple negative breast cancer.

For more information, please visit the Company website at www.quadrigabiosciences.com.